---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-26-002410"
form_type: "8-K"
ticker: "IGC"
cik: "0001326205"
company_name: "IGC Pharma, Inc."
filed_at: "2026-06-08T20:03:16+00:00"
generated_at: "2026-06-08T20:04:49.799599+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# IGC Pharma extends $12M loan agreement with O-Bank; facility fee rises to $60,000

## Summary
- Entered amendment to extend Master Loan and Security Agreement with O-Bank Co., Ltd.
- Facility maximum aggregate limit remains $12,000,000 unchanged from 2025.
- Facility fee increased from $48,000 to $60,000; other terms substantially unchanged.
- Loan agreement continues the general banking facility arrangement originally dated June 24, 2025.

## SEC filing metadata
- accession: 0001185185-26-002410
- form_type: 8-K
- ticker: IGC
- cik: 0001326205
- company_name: IGC Pharma, Inc.
- filed_at: 2026-06-08T20:03:16+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326205/000118518526002410/0001185185-26-002410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326205/000118518526002410/igc8k060826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-26-002410
- JSON: https://secwatch.observer/filing/0001185185-26-002410.json
- Plain text: https://secwatch.observer/filing/0001185185-26-002410.txt

## Key facts
- Material Agreements
  IGC Pharma, Inc. entered into Amendment to Master Loan and Security Agreement with O-Bank Co., Ltd. valued at Facility limit of $12,000,000; facility fee increased from $48,000 to $60,000 (effective 2026-06-05).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: O-Bank Co., Ltd.
  - Value: Facility limit of $12,000,000; facility fee increased from $48,000 to $60,000
  - Effective: 2026-06-05
  source text: On June 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter (collectively, the “Loan Agreement”) with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as lender (the “Lender”). The Loan Agreement continues the facility arrangement previously set forth in the General Banking Facility Letter dated June 24, 2025. The facility provides for a maximum aggregate limit of $12,000,000. The material terms of the facility remain substantially unchanged from the 2025 facility letter, except that the facility fee has increased from $48,000 to $60,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326205/000118518526002410/0001185185-26-002410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.